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Tumor vessels with resistance to anti-angiogenic therapy are characterized by the normaliza-
tion of the vascular structures through integration of mature pericytes and smooth muscle
cells (SMC) into the vessel wall, a process termed vessel stabilization. Unfortunately,
stabilization-associated vascular remodeling can result in reduced sensitivity to subsequent
anti-angiogenic therapy. We show here that blockade of VEGF by bevacizumab induces
stabilization of angiogenic tumor blood vessels in human tumor specimen by recruiting
Nestin-positive cells, whereas mature vessels down-regulated Nestin-expression. Using
xenograft tumors growing on bone-marrow (BM) chimera of C57Bl/6 wildtype and Nestin-
GFP transgenic mice, we show for first time that Nestin(+) cells inducing the maturation
of tumor vessels do not originate from the BM but presumably reside within the adventitia
of adult blood vessels. Complementary ex vivo experiments using explants of murine aor-
tas revealed that Nestin(+) multipotent stem cells (MPSCs) are mobilized from their niche
and differentiated into pericytes and SMC through the influence of tumor-cell-secreted fac-
tors. We conclude that tissue-resident Nestin(+) cells are more relevant than BM-derived
cells for vessel stabilization and therefore have to be considered in future strategies for
anti-angiogenic therapy. The identification of proteins mediating recruitment or differentia-
tion of local Nestin(+) cells with potential stem cell character to angiogenic blood vessels
may allow the definition of new therapeutic targets to reduce tumor resistance against
anti-angiogenic drugs.
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INTRODUCTION
Abnormal vasculature is a hallmark of solid tumors. Deregulated
formation of new blood vessels leads to a pre-dominance of imma-
ture blood vessels with patchy endothelial lining. Moreover, the
newly formed vessels cannot actively respond to physiological
stimuli because they lack the smooth muscle elements in their
walls (1). Consequently, tumor vessels prove to be functionally
inferior. The resulting undirected blood flow with areas of over-
supply as well as areas of undersupply complicates an efficient
administration of intravenous drugs in cancer therapy (2). How-
ever, the vascular network can mature by recruitment of pericytes
and smooth muscle cells (SMC) to stabilize the immature tumor
vessels and this process is accelerated when anti-angiogenic agents
were used (3, 4). Though there is some evidence that pericytes and
SMC might originate from multipotent mesenchymal stem cells
the origin of these mural cells and the molecular changes associ-
ated with pericyte-mediated vascular remodeling are still poorly
understood (5, 6).
Angiogenesis inhibitors such bevacizumab are used as anti-
cancer agents and decrease tumor growth. Bevacizumab is a
humanized monoclonal anti-VEGF antibody that prevents the
interaction of VEGF with the corresponding VEGF receptors
by neutralizing all VEGF isoforms (7, 8). Paradoxically, anti-
angiogenic therapies promote vascular remodeling within the
respective tumors resulting in stabilization of the newly formed
tumor blood vessels (9, 10). Herein, normalization is achieved by
the recruitment and integration of mature pericytes into the ves-
sel wall for capillaries as well as SMC for larger vessels (11, 12).
Notably, remodeling of the tumor vasculature leads to increased
resistance of stabilized vessels to further anti-angiogenic therapies
(10, 13).
Consequently, there is an urgent need for the development
of second-generation anti-angiogenic therapies. Such therapies
may balance initial vascular stabilization with a subsequent de-
stabilization to make the remaining vessels susceptible to a sec-
ond wave of anti-angiogenic therapy (14). Thus, targeting both,
endothelial cells and pericytes, could be an alternative promis-
ing approach to improve anti-angiogenic treatment for malignant
tumors (15).
An improved understanding of the origin of pericytes and SMC
and of the signals driving their recruitment and differentiation
is necessary to efficiently target stabilization-associated vascular
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remodeling to improve anti-angiogenic anti-cancer therapies. We
recently demonstrated that vascular wall-resident CD44(+) mul-
tipotent stem cells (VW-MPSCs) within the adult human vascular
adventitia are capable to differentiate into pericytes and SMC (5).
We assume that on the basis of their anatomic location such vessel-
resident stem cells are available as first point of contact for tumor
cells and secreted factors (16, 17).
Here, we aimed to gain insight into the use of Nestin as a
marker for the origin of mural pericytes and SMCs in vascu-
lar stabilization processes during tumor progression. For this,
we first examined Nestin-expression in human tumor specimen.
Moreover, we used the transgenic Nestin-GFP mice as well as bone-
marrow (BM) chimera of C57Bl/6 wild type (wt) and Nest-GFP
mice to trace the recruitment Nestin(+) MPSCs during vascular
remodeling of tumor blood vessels in xenograft tumors and to ana-
lyze the relative importance of tissue-resident Nestin(+) MPSCs
vs. circulating (BM-derived) MPSC. Our data demonstrate that
tissue-resident Nestin(+) progenitor cells are indeed the major
source for pericytes and SMC in vascular remodeling processes.
The identification of Nestin as a novel marker for mural pericytes
will facilitate future investigations about the mechanisms driving
their recruitment and differentiation.
MATERIALS AND METHODS
REAGENTS AND ANTIBODIES
Nestin antibody was from Acris Antibodies (Herford, Germany),
alpha smooth muscle actin (SMA) and CD34 antibodies were from
Santa Cruz (Santa Cruz, USA), CD31 antibody was from Dianova
(Hamburg, Germany), and GFP antibody was from Thermo Sci-
entific (Dreieich, Germany). Peroxidase and fluorescence-labeled
secondary antibodies were from Jackson IR Laboratories (West
Grove, USA).
HUMAN TUMOR TISSUE
Tissues from human liver metastases were taken at clinical relapse
in patients having developed colorectal adenocarcinoma and
undergoing neoadjuvant treatment using bevacizumab and reg-
ular chemotherapy and were obtained during surgery according
to local ethical and biohazard regulations. Surgical pathology
diagnoses were made based on current WHO criteria. Resected
tissue specimens were processed for further pathological diagnos-
tic routine in a standardized way as previously described (14). The
local ethical review committee of the University Hospital Essen
approved all studies including human tissue specimen. Informed
consent (written form, Nr. 10-4363) was obtained.
CELLS AND TUMOR MOUSE MODEL
The mouse melanoma cell line B16F10 and the Lewis lung car-
cinoma (LLC) cell line was obtained from ATTC (Rockville, MD,
USA). Cells were cultured in DMEM with 10% FCS, 100 U/mL
penicillin and streptomycin in a humidified atmosphere (5% CO2
at 37°C) and passaged twice a week. A mouse tumor model was
used as described before (18). In brief, BM cells were harvested
aseptically by flushing the tibias and femurs of adult animals and
subjected to erythrocytes lysis. C57Bl/6J mice were lethally irra-
diated with a split dose (7+ 3 Gy) of a X-ray source and were
intravenously transplanted with 1× 106 unfractionated murine
Nest-GFP-expressing BM cells from Nest-GFP transgenic donor
mice into the tail vain (19). B16F10 and LLC cells were harvested
by a brief trypsinization (0.05% trypsin/0.02% EDTA), washed,
and resuspended in PBS at a density of 1× 107 cells/mL. After
hematopoietic reconstitution, B16F10 or LLC cells were subcuta-
neously implanted into the flank of the mice. Up to 20 animals
of each experimental group received a single subcutaneous injec-
tion of 1× 106 viable tumor cells. After around 21 days of tumor
growth animals were sacrificed and tumors were harvested and
subdivided in four parts. One part was freshly frozen in OCT
Tissue Tek (Sakura) for immunofluorescence staining, the second
part was fixed in 4% PFA and paraffin embedded for immuno-
histochemical staining, the other two parts were fresh frozen in
liquid nitrogen and prepared for protein or RNA analyses. In
addition, a vice-versa experiment was performed. Here, Nest-GFP
mice were lethally irradiated and BM cells from C57Bl/6 wt donor
mice were transplanted. Experiments were repeated three times.
All procedures involving mice were conducted in accordance with
protocols approved by the local institutional Animal Care Com-
mittee (Regierungspräsidium Düsseldorf Az 84-02.04.2012.A137;
84-02.04.2012.A034).
HEMATOPOIETIC ENGRAFTMENT ANALYSIS
To confirm the hematopoietic engraftment, peripheral blood
analyses were performed via blood count measurement (VetABC)
and flow cytometry. Blood samples were obtained from tail vein
before tumor implantation and from heart when the mice were
sacrificed, and subjected to erythrocyte lyses. Engraftment was
accessed by the percentage of GFP(+) cells in blood samples and
in BM. Samples were examined in two-color FACS using Cellquest
software (Becton Dickinson, Heidelberg, Germany).
ISOLATION AND PURIFICATION OF TISSUE-RESIDENT-MPSCs
Mice were scarified after transcardial perfusion with PBS and
aortas were removed. Isolated aortas were excised under a dis-
section microscope and contaminating fatty and muscle tissue
was removed. After several washes, vessels were mechanically
minced and dissociated for 10–15 min at 37°C in OptiMEM I
medium (GIBCO) containing 0.2% type 2-collagenase (Worthing-
ton, Lakewood, USA). On dissociation, cells were washed twice
in PBS containing 5% FCS (300× g, 10 min, 4°C). Cellular sus-
pensions were passed through 70µm pore size filters. Nest-GFP-
expressing cells were further purified using fluorescent activated
cell sorting based on their GFP-expression and plated in 96 well
plastic dishes (one cell per well). Primary Nest-GFP cells were
cultivated using complete DMEM supplemented with 20% FCS.
TRILINEAGE DIFFERENTIATION ASSAY
Differentiation of cultivated MPSCs into adipocytes, chondro-
cytes, and osteocytes was done using ready-to-use differentiation
media from Lonza (hMSC Differentiation BulletKit – Adipogenic,
PT-3004; – Chondrogenic, PT-3003; – Osteogenic, PT-3002)
according to the manufactures instructions. Adipogenic differen-
tiation was verified using Oil red staining, chondrogenic differen-
tiation was verified using Collagen type II antibody (Santa Cruz)
and immunohistochemitry and osteogenic differentiation was ver-
ified using NBT/BCIP staining (Sigma) for alkaline phosphatase
activity.
Frontiers in Oncology | Molecular and Cellular Oncology June 2014 | Volume 4 | Article 169 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Klein et al. Nestin(+) MPSCs stabilize angiogenic vessels
CONDITIONED MEDIA
B16F10 and LLC cells were cultured as described above. When cells
were grown to confluence, media were replaced and cells were cul-
tured in the presence of 0.5% fetal bovine serum for 24 h before
collection of media. Control medium was incubated for the same
time in the incubator without cells.
ARTERIAL RING ASSAY
Isolated mouse aortas were cut into 2 mm thick rings and placed
into a 48-well tissue culture plate within PureCol® collagen-
gel (Advanced BioMatrix, Denver). After polymerization normal
growth medium (EGM-2 medium, PromoCell) was added and the
rings were further incubated at 37°C in normal growth medium
alone, or supplemented with conditioned medium (ratio 1:1). The
medium was changed every third day. Capillary outgrowth was
analyzed using light microscopy at indicated time points.
IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE
Paraffin embedded tissue sections were hydrated using a descend-
ing alcohol series, incubated for 10–20 min in target retrieval solu-
tion (Dako) and incubated with blocking solution (2% FCS/PBS).
After permeabilization, sections were incubated with primary anti-
bodies over night at 4°C. Antigen was detected with a peroxidase-
conjugated secondary antibody (1/250) and DAB staining (Dako).
Nuclei were counterstained using hematoxylin. For immuno-
fluorescence analysis, the antigen was detected with an anti-
rabbit-Alexa488 and anti-mouse-Alexa555-conjugated secondary
antibody (1/500). Hoechst 33342 (Invitrogen, Karlsruhe, Ger-
many) was used for nuclei staining. Specimens were analyzed
by confocal microscopy. Quantification was done by counting
numbers of specific immunoreactive structures in four ran-
domly chosen optical fields using the indicated microscopes.
Data are presented as mean± SEM from four independent
experiments.
WESTERN BLOT
Whole cell lysates were generated by scraping cells into ice-
cold RIPA-P buffer (150 mmol/L NaCl, 1% NP40, 0.5% sodium-
desoxycholate, 0.1% sodium-dodecylsulfate, 50 mmol/L Tris/HCL
pH 8, 10 mmol/L NaF, 1 mmol/L Na3VO4), supplemented with
complete Protease-Inhibitor-Cocktail (Roche) and performing
2–3 freeze-thaw cycles. Protein samples (50–100µg total pro-
tein) were subjected to SDS-PAGE electrophoresis and Western
blots were done as previously described using GFP (1/1000) or
beta-actin (1/5000) antibodies (20).
ELECTRON MICROSCOPY
Tumor tissues were fixed with cacodylat buffered glutaraldehyde
(2.5%), contrasted with 1% osmium tetroxide and 1% uranylac-
etate and embedded in EPON. Thin sections (70 nm) were cut
and mounted on 200 Mesh hexagonal cooper grids. For con-
trast enhancement uranylacetate and lead citrate were applied.
Sections were analyzed using a Zeiss transmission electron micro-
scope (EM 902A) at 8 KV. Digital image acquisition was performed
on a Morula slow-scan-CCD camera connected to a PC running
ITEM 5.0 software.
STATISTICAL ANALYSIS
Paired or unpaired two-tailed t -tests were performed using
GraphPad InStat3 software depending on effective matching of
analyzed data. SD or SEM are indicated by error bars. Significance
was assumed for p-values≤ 0.05, *≤0.05, and **≤0.01.
RESULTS
NESTIN-EXPRESSION SERVES AS NOVEL SELECTIVE MARKER FOR
VASCULAR MURAL CELLS
In order to investigate, if Nestin-expression might serve as novel
and selective marker for newly formed tumor blood vessels,
we analyzed angiogenic vessels in tumor specimen from cancer
patients (Figure 1). Human liver metastases were collected at
clinical relapse in colorectal cancer patients with or without anti-
angiogenic treatment with bevacizumab. Interestingly, Nestin(+)
cells were mobilized to the newly formed blood vessels suggesting
that these cells might have been derived from Nestin(+) tissue-
resident MPSCs (Figure 1A). In bevacizumab-treated tumor spec-
imen a more intense expression of Nestin in vascular mural cells
and a more regular arrangement of Nestin(+) cells around newly
formed tumor blood vessels was detected when compared to
untreated tumor tissue, indicating vessel stabilization, maturation,
and thus normalization of the vascular bed upon anti-angiogenic
treatment (Figure 1B). In contrast, mature vessels were either
negative or only slightly positive for Nestin. This suggests, that
upon differentiation into SMC Nestin(+) tissue-resident MPSCs
down-regulate Nestin-expression.
A detailed morphological analysis showed that Nestin-
expression was restricted to the mural cells, particularly pericytes
(Figures 1A,B). Of note, Nestin could not be detected in endothe-
lial cells of newly formed tumor blood vessels. This result was
confirmed by the lack of co-localization of CD31 and Nestin
immunoreactivity in immunofluorescence analysis (not shown).
Similar expression patterns were observed in vessels of
human melanoma samples: angiogenic vessels within the tumor
were stabilized by Nestin(+) cells, whereas mature vessels
in tumor-surrounding tissue down-regulated Nestin-expression
(Figure 1C).
TISSUE-RESIDENT GFP(+) PERICYTES CLOSELY ASSOCIATE WITH
ANGIOGENIC VESSELS IN TUMORS GROWN IN Nest-GFP TRANSGENIC
MICE
Next, we analyzed the putative contribution of tissue-resident
MPSCs as compared to BM-derived MSCs to the formation of
newly formed tumor blood vessels. We performed a BM trans-
plantation (BMT) experiment. To track tissue-derived cells in vivo,
wt BM cells were isolated from C57BL/6 mice and transplanted
into lethally irradiated age-matched, syngenic, Nest-GFP trans-
genic recipients (NestwtBM), and vice-versa. Peripheral blood
analysis was done 6 weeks post-transplantation and showed a
complete engraftment of implanted donor BM as shown by the
reconstitution of BM-GFP(+) cells of wt transplanted littermates
with GFP(+) cells (Figure 2, wtNestBM). This indicates a stable
replacement of original host stem cell population by donor cells.
Subcutaneously grown B16F10 melanomas and LLC were
then generated by implantation of these cells into the flank of
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FIGURE 1 | Immunohistological analysis of Nestin-expression in vessel
structures in bevacizumab-treated human tumor tissues.
(A) Paraffin-sections of liver metastases from colon carcinoma patients
without neoadjuvant treatment (Control) were stained for Nestin. Scale bar
50µm. (B)Treatment group: sections of liver metastases from colon
carcinoma patient having received bevacizumab. Representative images of
19 tissue samples are shown (9 treatment and 10 control samples). Scale
bar 20µm. (C) Paraffin-sections of human melanoma tissue sections as
well as human colon tissue sections were stained for Nestin. Sections
were counterstained with hematoxylin. Art, artery; lart, liver artery; pv,
portal vein; bd, bile duct; ft, fatty tissue; cry, crypt. Scale bar 10µm.
reconstituted mice as well as in untreated Nest-GFP control mice
(Figure 3, B16F10 and Figure 4, LLC).
Tumor and surrounding tissues were removed at day 21 and
subjected to immunofluorescence analysis. Interestingly, many
Nest-GFP(+) cells were detected in the tumor bed of B16F10
tumors and were closely associated with newly formed CD31(+)
blood vessels. These cells resembled differentiated SMA(+) peri-
cytes indicative for blood vessel maturation (Figure 3A). Impor-
tantly, in the reconstituted animals GFP(+) cells lining the tumor
vessels were only detected in NestwtBM mice but not in wtNestBM
mice indicating that tissue-resident and not BM-derived cells
serve as source for pericytes in vascular remodeling processes
(Figures 3B,C). Notably, no co-localization of GFP(+) cells with
endothelial markers could be found.
Quantification of Nest-GFP(+) cells associated with newly
formed blood vessels in NestwtBM mice and wtNestBM mice indi-
cated that all GFP(+) cells were derived from the host (Figure 3D).
In tumor adjacent tissue, only single GFP(+) cells were detected
close to larger vessels, in association to myofibrils or in tissue
fat (not shown). Of note, the vast majority of SMA(+) peri-
cytes and SMC expressed GFP(+) indicating their origin from
the host. In line with these findings, the GFP protein was only
detected in Westernblot analyses of tumors grown in Nest-GFP
animals reconstituted with BM from wt mice (NestwtBM) but
not in wt mice reconstituted with BM of Nestin transgenic mice
(wtBMNest). These findings corroborate that tissue-resident and
not BM-derived GFP(+) pericytes stabilize angiogenic tumor
vessels (Figure 3E).
To corroborate our findings in another tumor model, analo-
gous analyses were performed with the LLC xenograft tumors.
As shown in Figure 4, a similar pattern of Nest-GFP-expression
was observed in LLC tumors grown on BM chimera of C57Bl/6
wt and Nest-GFP transgenic mice: many Nest-GFP(+) cells were
tightly associated with newly formed CD31(+) vascular structures
(Figure 4A). Moreover, GFP(+) cells surrounding tumor vessels
were only detected in NestwtBM.
To further confirm that tissue-resident GFP(+) cells and not
BM-derived cells contribute to vascular remodeling processes one
group of irradiated wt animals received NestBM for hematopoi-
etic reconstitution, which was supplemented with BM-derived
EGFP-labeled MSC (Figure 4B). Again, no GFP(+) cells could
be detected in tumor specimen.
Subsequent electron microscopic analysis further indicated that
pericytes and SMCs not only associate to but properly integrate
into tumor blood vessels (Figure 5). At the structural level, the
pericytes assembled to new capillaries. Moreover, in some tumor
vessels they seemed to be more regularly integrated into the wall
of new capillaries because of their tight contact to the endothe-
lial cells, e.g., sharing the same basement membrane (bMem),
indicating vessel stabilization and maturation (Figure 7, bold
arrows).
Taken together, the vast majority of SMA(+) pericytes
expressed GFP(+) in reconstituted NestwtBM mice. This indi-
cated that tissue-resident Nest-GFP(+) pericytes stabilize angio-
genic vessels in tumors grown in Nest-GFP mice and highlight the
general relevance of these cells in tumor neovascularization.
Nest-GFP(+) CELLS PREDOMINANTLY RESIDE IN CLOSE ASSOCIATION
WITH ARTERIES AND EXHIBIT TYPICAL MSC CHARACTERISTICS
To gain further insight into the identity of the Nestin(+) cells,
we next analyzed whether Nest-GFP(+) cells are also localized in
the vascular adventitia of murine aorta under physiological con-
ditions (Figure 6). As expected, in electron microscopic analysis
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FIGURE 2 | Nest-GFP+ cells in the peripheral blood and BM of
Nest-GFP mice. (A) Nest-GFP transgenic mice were lethally irradiated with
a split dose of 7+3 Gy total body irradiation and subsequently adoptively
transferred with 2×106 murine wt BM cells from C57BL/6 donor mice into
the tail vain (NestwtBM) and vice-versa (wtNestBM). One group of
irradiated animals received NestBM for hematopoietic reconstitution which
was supplemented with cultured EGFP(+) MSCs derived from the
bone-marrow of C57BL/6-Tg(CAG-EGFP)1Osb/J mice [NestBM+EGFP(+)
MSC]. After hematopoietic reconstitution (6–8 weeks after transplantation)
blood samples were taken, erythrocytes were removed, and analyzed for
GFP-expression by immunofluorescence. Lymphocytes are stained in red.
(B) Paraffin-sections of Nest-GFP BM specimen were stained for
GFP-expression. (C)The blood analysis showed a complete engraftment of
donor BM by the donor BM-derived Nest-GFP transplanted progenitor cells
and vice-versa as indicated by GFP-expression. Control, normal Nest-GFP
transgenic mice.
we found undifferentiated cells in the adventitia of mouse aortas
(Figure 6A). Immunostaining of murine aorta sections using anti-
bodies against GFP and Nestin identified Nest-GFP(+) cells near
by the SMC layer, the tunica media. GFP(+) cells were negative
for CD34, a marker for endothelial and hematopoietic progenitors
(not shown).
Next, we isolated the GFP(+) cells from the aortic wall by a
short collagenase digestion of mechanically minced adventitial
tissue fractions prepared from whole ex vivo-isolated aortas. Sub-
sequent FACS analysis revealed that 0.28% (±0.12) of the cells in
the primary isolate were GFP(+). After a selective adherence on
plastic dishes, we further characterized the isolated GFP(+) cells
in vitro (Figure 6B). In vitro clonally expanded cells were Nest-
GFP(+) and differentiated into adipocytes, chondrocytes, as well
as into osteoblastic cells demonstrating a classical mesenchymal
stem cell-like behavior.
We then performed ring assay studies using small mouse
aorta fragments to test whether GFP(+) cells can be mobi-
lized from their niche in response to tumor-secreted factors
(Figure 7A). Quantitative measurements revealed that cells from
the explanted vessels showed a significantly increased in-gel
sprouting phenotype whenever aorta fragments were treated with
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FIGURE 3 |Tissue-resident Nest-GFP(+) cells and not BM-derived
MSCs contribute to remodeling of tumor blood vessels. (A) B16F10
tumor cells were subcutaneously transplanted into the flank of Nest-GFP
mice. Tumors were removed 21 days after tumor induction and subjected
to immunofluorescence analysis. Vessels were stained for CD31
(endothelial cells), smooth muscle actin (SMA; pericytes/SMC), and GFP
or Nestin, respectively. Control sections were stained with isotype
controls. Nest-Control, Nest-GFP transgenic mice. Scale bar 15µm.
(B) Immunofluorescence analysis of B16F10 tumors grown
subcutaneously in the flank of BM-reconstituted Nest-GFP mice.
NestwtBM, Nest-GFP mice received bone-marrow (BM) from wt (C57Bl/6)
mice after lethally total body irradiation (7+3Gy). (C) Experiment with
reciprocal BM chimera as shown in (B). wtNestBM, wt mice received
bone-marrow (BM) from Nest-GFP mice after lethally total body irradiation.
Scale bar 20µm. (D) GFP-expression was quantified by counting GFP- and
SMA-immunoreactive vascular structures (pericytes/SMC-stabilized
vessels). (E) GFP-expression was further analyzed using Western blot
analysis.
tumor-cell culture supernatants derived from B16F10 and LLC
cells (Figure 7B). These findings suggest that tumor-cell-derived
soluble factors promote MPSC mobilization and invasion.
GFP(+) cells were found within the Matrigel after 7–14 days of
culture indicating that GFP(+) cells are capable to migrate out of
the vessel wall whereas the SMC layer seemed to remain intact. Of
note, when cultured in the presence of tumor-cell supernatants
the GFP(+) cells became also positive for the pericyte/SMC
marker SMA whereas untreated GFP(+) cells lacked SMA expres-
sion (Figure 7C). This indicates that mobilized GFP(+) cells are
capable to differentiate into SMA(+) pericytes and SMCs under
the influence of tumor-cell-secreted factors.
DISCUSSION
Interest is increasing in identifying the origin and the localiza-
tion of pericytes and SMC in tumor tissue specimens from cancer
patients and to gain a better understanding of their role in tumor
growth and the outcome of anti-cancer therapies.
Here, we show for the first time that a prominent stabilization
of tumor vessels in human colorectal adenocarcinoma metastases
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FIGURE 4 |Tissue-resident Nest-GFP(+) pericytes associate with
angiogenic vessels in LLC tumors grown in Nestin-GFP mice.
(A) Immunofluorescence analysis of LLC tumors grown subcutaneously
in the flank of wt BM-reconstituted Nest-GFP mice (NestwtBM). Tumors
were isolated at day 21 and subjected for immunofluorescence analysis.
Vessels were stained for CD31 or SMA and GFP. (B) Experiment with
reciprocal BM chimera as shown in (A). wtNestBM, wt mice having
received BM from Nest-GFP mice after total body irradiation. To further
confirm that tissue-resident MSCs and not BM-derived MSCs contribute
to vascular remodeling processes one group of irradiated animals
received NestBM for hematopoietic reconstitution that was
supplemented with BM-derived EGFP-labeled MSC. Control sections
were stained with isotype controls. Scale bar 20µm.
(C,D) GFP-expression was quantified by counting GFP and
SMA-immunoreactive vessels and further analyzed using Western blot
analysis.
under clinical treatment with bevacizumab is achieved by a much
more pronounced integration of Nestin(+) cells into the wall
of maturing vessels, whereas mature vessels from the tumor-
surrounding area or healthy tissue were characterized by decreased
Nestin-expression. Moreover we provide evidence that Nestin(+)
MPSCs inducing the maturation of tumor vessels do not originate
from the BM but presumably reside within the adventitia of adult
blood vessels and are mobilized from their niche and differenti-
ated into pericytes and SMC in the presence of tumor-cell-secreted
factors.
Our findings suggest Nestin as a novel marker of pericytes
and pericyte-like mural cells and thus of vascular maturation.
Immunostaining of tissue specimen for Nestin may therefore be
of use as a prognostic marker to evaluate the extent of vessel mat-
uration in cancer specimens. Even more important, a selective
detection of newly formed tumor vessels within cancer tissues
using specific markers raises the possibility of molecular targeted
therapy via the inhibition of tumor angiogenesis (21).
In line with our assumption, it was shown that expression
of Nestin is specific to developing vascular smooth muscle cells
(VSMC) whereas differentiated, postmitotic VSMC are negative
for Nestin (22). Generally, expression of the intermediate filament
protein Nestin has been detected in repair processes and in various
neoplasms and has been associated with immature and angiogenic
blood vessels including proliferating vascular endothelial cells
(21). In contrast, we did not detect any single Nestin(+) endothe-
lial cell, neither in the murine models nor in different human
(tumor) specimen investigated here. One reason for this might
be a different staining pattern of the different antibodies used to
detect Nestin in different specimen. In addition, no differentiation
of hMPSCs to endothelial cells was detected in vitro (23, 24).
Consistent with our findings about a role of Nestin(+) tissue-
resident MPSCs as major source for pericytes and SMC in vas-
cular remodeling processes, Nestin(+) pericytes have recently
been identified as the progenitors of all Leydig cell phenotypes in
another Nest-GFP transgenic mouse model. Consistent with our
observations, Nestin-expression was also not detected in endothe-
lial cells in that model. These findings implicate that similar to
adult stem cells vascular-resident progenitor cells also play a critical
role in organ formation (25).
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FIGURE 5 | Ultrastructural analysis of angiogenic tumor vessels.
Subcutaneously grown B16F10 tumors were removed 21 days after tumor
induction and subjected to electron microscopic analysis. A defective and
irregular basement membrane (bMem) lining angiogenic endothelial cells (EC)
is emphasized by an asterix (*), a regular bMem assembly is depicted by a
bold arrowhead. Arrows highlight partially degraded mitochondria in EC. PC,
pericyte; SMC, smooth muscle cell; TC, tumor-cell; exC, extravasated cell; Lu,
lumen. Representative images of three independent experiments are shown.
Despite the controversy whether Nestin-expression is restricted
to angiogenic endothelial cells or to Nestin(+) stem cells that asso-
ciate and integrate into newly formed blood vessels, our results still
endorse the idea that a Nestin-targeted therapy may be suited to
selectively suppress tumor proliferation via inhibition of neovas-
cularization and vessel stabilization in numerous malignancies,
including colorectal cancer and melanomas.
Though improved clinical outcomes have been observed when
combining anti-angiogenic drugs with chemotherapy for many
types of human cancers, clinical efficacy of these treatment strate-
gies has not been as successfully as initially hoped. This may at least
be partially due to the fact that anti-angiogenic drugs trigger vas-
cular stabilization involving pericyte-coverage and that pericyte-
coverage impairs further tumor vessel regression in response to
anti-angiogenic treatment (26). In contrast, the presence of VEGF
led to ablation of pericyte-coverage on nascent vascular sprouts
and vessel de-stabilization (27). Thus, targeting pericyte recruit-
ment, coverage and function in addition to endothelial cells may
be suited to promote progress in anti-angiogenic tumor therapy
(28, 29).
Our findings about the origin of vascular-stabilizing pericytes
provide a further basis for the design of novel strategies to improve
anti-angiogenic therapies. Our data clearly show that (i) Nestin-
expression serves as novel selective marker for newly formed tumor
blood vessels during the process of vascular remodeling and (ii)
that Nest-GFP(+) MPSCs are directly involved in vascular remod-
eling processes in terms of vascular stabilization, serving as a local
source for pericytes and SMC (14).
Up to now, the origin of pericytes in tumors and the mole-
cular mechanisms that govern their recruitment and association
with tumor vessels is not well understood. It has been suggested
that endothelial-derived PDGF-B triggers the recruitment of per-
icytes to mature, remodel, and stabilize newly formed vessels so
that immature vessels with or without pericytes are formed (30).
However, the role of BM-derived vascular progenitor cells vs.
tissue-resident stem cells in neovascularization is still controver-
sial. Several reports suggest that adult neovascularization involves
BM-derived endothelial progenitor cells (BM-EPCs) providing an
alternative source of endothelial cells in the process defined as
post-natal vasculogenesis (31, 32). On the basis of these obser-
vations BM-EPCs are thought to represent a new and promising
target for pro- or anti-angiogenic treatment strategies (33). How-
ever, the exact role of these cells in post-natal vasculogenesis and
their contribution to vascularization of primary tumors is not yet
clear; the respective values range from 50% incorporated BM-
EPCs to undetectable numbers (34, 35). In contrast, our findings
in tumors grown on reconstituted NestwtBM mice revealed that
exclusively SMA(+) pericyte-like cells expressed GFP demonstrat-
ing that Nest-GFP(+) pericytes derived from tissue-resident cells
and not from the BM stabilize angiogenic vessels in the tumors.
Electron microscopy as well as immunofluorescence analyses
on murine aorta sections support the presence of undifferenti-
ated Nest-GFP(+) cells in the adventitia of mouse aortas under
physiological conditions. Furthermore, isolated Nest-GFP(+) cells
from mouse aortas exhibited typical MSC characteristics. Our
ex vivo experiments with murine aorta rings showed in addi-
tion that these cells can be mobilized from their niche by factors
secreted from cultured tumor-cell lines and are capable to dif-
ferentiate into pericytes and SMC. According to the guidelines,
clonally expanded cells adhered on plastic, differentiated into
adipocytes, chondrocytes, and osteocytes under certain cell culture
conditions (36).
Recently, it has been elegantly shown that Nest-GFP(+) cells
in the BM are enriched in mesenchymal stem cell activities and
were pericytes-like (37). Further studies are needed to investigate
the role of Nestin-expression in developing pericytes as well as
during SMC differentiation. There is an urgent need in identi-
fying cells and signaling molecules that are selectively regulated
during the process of new vessel formation and vascular remodel-
ing. Here, we suggest that the vascular adventitia serves as a niche
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FIGURE 6 | Nest-GFP(+) cells are localized in the vascular adventitia of
murine aorta. (A) Electron microscopic analysis indicates the presence of
undifferentiated cells [putative stem cells (SC) in the vasculogenic zone (Ad)
of the adventitia (A)]. eEM, external elastic membrane; Coll, collagen. Ex
vivo-isolated aortas from Nest-GFP mice were digested by a short incubation
in collagenase solution and sorted by FACS based on the GFP-expression.
Immunofluorescence analysis for Nest-GFP(+) MSCs in their native niche was
performed using double immunostainings on mouse aorta sections
combining antibodies against GFP (green) and SMA (red). Dotted line marks
the border between media and adventitia of the aorta wall. Scale bar 20µm.
(B) Verification of trilineage differentiation. Clonally expanded Nest-GFP(+)
were subjected to in vitro differentiation into adipocytes, chondrocytes, and
osteocytes. Differentiation was observed within 14 days after induction of
differentiation as shown by Oil red staining, by immunostaining for collagen
type II (Coll II) and by histochemical staining for alkaline phosphatase (ALP).
Magnification 620×.
for Nest-GFP(+) MPSCs thereby supporting previous studies that
the distribution of MSCs throughout the post-natal organism is
related to their existence in a perivascular niche (38). It is well
known that SMC can arise from multiple sources (39). Lineage
tracing studies might help to investigate whether the origin of
vascular SMCs is restricted to Nest-GFP(+) MPSCs, which are
supposed to reside within the wall of arterial blood vessels as
presented here.
In summary, we show here that tissue-resident Nestin(+)
MPSCs are more relevant than BM-derived cells for vessel sta-
bilization and serve as a local source for pericytes and SMC. Thus,
tissue-resident Nestin(+) MPSCs may be a promising target for
anti-angiogenic therapies. The identification of proteins medi-
ating the recruitment of local Nestin(+) cells with potential
stem cell character to angiogenic blood vessels and of their dif-
ferentiation into mural cells may allow the definition of new
therapeutic strategies to counteract pathologic vascular remod-
eling and to reduce tumor resistance against anti-angiogenic
drugs.
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FIGURE 7 | B16F10 and LLC tumor-cell supernatants increase the
mobilization and in-gel sprouting of mouse aorta cells and induce
Nest-GFP MPSC differentiation into pericytes. (A) Mouse aorta fragments
of Nest-GFP transgenic mice embedded in Collagen-gel were exposed to
B16F10 and LLC cell culture supernatants (SN) or control supernatants,
respectively. In-gel sprouting and gel invasion was followed by phase contrast
microscopy for 14 days. (B)The distance of capillary-like sprouts was
measured to quantify the invasion. Data are presented as mean±SD from
four independent experiments measured at least two times each. *p≤0.05;
**p≤0.005. (C) Collagen gels were fixed, paraffin embedded, and tissue
sections were subjected for immunofluorescence using antibodies against
GFP (green) and SMA (red). Scale bar 10µm.
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